There are many ways of predicting cancer recurrence and survival; these include pathology-based tests, such as tumor grade, molecular markers, such as mutations, and the TNM staging classification. However, the recently developed immunoscore, which evaluates cancer recurrence and survival through analysis of the patients adaptive immunity, has recently shown to be a more powerful predictor than all of these, as explained here by Jerome Galon, PhD, of Cordeliers Research Center, Paris, France, at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.
The immunoscore: the most powerful predictor of cancer recurrence and survival
